GSK_ Annual_Report_2021-22

93 Leadership Indicators 1. Does the entity extend any life insurance or any compensatory package in the event of death? Your Company has a Group Life Insurance coverage and Accidental Life Insurance coverage, which is extended to our employees. 2. Does the entity provide transition assistance programs to facilitate continued employability and the management of career endings resulting from retirement or termination of employment? (Yes/ No) Transition Assistance is provided for employees whose employment is terminated due to Job redundancies. 3. Details on assessment of value chain partners All the value chain partners are subject to Third party risk assessment (TPRA) on induction. The outcome of such assessment highlights the risks associated in dealing with such vendors on various parameters like environment, health & safety, labour rights, Privacy, crisis & continuity management, ABAC, etc. and the mitigation actions are agreed. Further, background checks are conducted which help in early identification of any red flags associated in dealing with such vendors. 4. Provide details of any corrective actions taken or underway to address significant risks / concerns arising from assessments of health and safety practices and working conditions of value chain partners. Health and safety conditions and working conditions As part of your company’s onboarding process for all third-party vendors/ suppliers/ contract manufacturers, various risks including labour rights and health and safety are assessed. The suppliers/ vendors/ contract manufacturers are evaluated on their existing policies and procedures for dealing with issues relating to sexual harassment, discrimination, child labour, forced labour, and fair wages. In the previous FY 2021-22, no physical audits, or assessments were carried out due to the pandemic. Third-party contract manufacturers Quarterly performance review of health and safety and incidents/ accidents if any is undertaken for key contract manufacturers. Based on the detailed SOP on Third Party Manufacturer EHS management Process, audits are carried out once in three years and various Corrective and Preventive Action (CAPA) plans are prepared and they are monitored closely. In addition, other programs relating to antimicrobial resistance, process safety management, and chemical exposure are undertaken. All key third party contract manufacturing sites have an internal committee comprising its site management and workers wherein all matters relating to working conditions and EHS are discussed. 3.4. Principle 4: Businesses should respect the interests of and be responsive to all its stakeholders Our continued focus on the quality of product delivery has enabled us to build trust with a broad range of stakeholders. This in return has sustained the success of our business and added value to our stakeholder relationships. During the course of our business, we engage with multiple stakeholder groups. Our stakeholder engagement and feedback mechanisms help us identify stakeholder expectations, conflicts and concerns. Essential Indicators 1. List stakeholder groups identified as key for the entity Stakeholder Group Channels of communication (Email, SMS, Newspaper, Pamphlets, Advertisement, Community Meetings, Notice Board, Website) , Other Frequency of engagement Purpose and scope of engagement including key topics and concerns raised during such engagement Patients and consumers Webcasts, Social media pages, Websites, Posters, Standees, Pamphlets, Face to face meetings Need based Disease awareness programs /Vaccination awareness programs are organized to educate the general public including patients about the signs, symptoms, diagnosis, treatment and prevention options for a disease to foster better patient outcomes through prevention, early diagnosis, and management to minimize or slow disease progression and complications. Healthcare Professionals (HCPs) Face to face, Emails, Webcasts, Social media pages, Doctor networking platforms, SMSs, Instant messaging platforms, Congress exhibits etc. Need based Keep the HCP abreast with the latest information on product and science, access to product and to gain understanding of the disease and its management. To provide avenues for HCPs to discuss and deliberate on latest data, clinical challenges, multidisciplinary expert discussions, new published data intending to help improve treatment outcomes for our patients.